GLP-1 Price War Winners
−2.6%
since Sep 9
The idea
I think weight-loss drug prices are absurdly high because two companies own the market, and that cracks over the next few years as rivals launch cheaper shots and pills. So I skip the duopoly entirely and own both sides of the shift instead: challengers racing new drugs through trials, plus the manufacturers, distributors, and trial runners who get paid more as volume rises no matter whose drug wins. I keep no single name above 6% and hold some cash on the side. I'd rethink this if the incumbents' prices hold firm or if trial setbacks stall the challengers for good.
What it owns
- Companies that make pens, cartridges, and fill vials get paid per dose regardless of who sells the drug, so volume growth lifts all of them. · Thermo Fisher ScientificIt fills syringes and makes drugs under contract for pharma companies that cannot build factories fast enough, getting paid regardless of whose drug wins., West Pharmaceutical ServicesIt makes the stoppers, plungers, and components inside injector pens, and every new shot on the market needs them., Stevanato GroupIt makes the glass cartridges and pen systems that weight-loss shots ship in and has been expanding capacity specifically for obesity drug demand., Becton DickinsonIt is the biggest syringe and injection-device maker, offering a diversified way to get paid as injection volumes climb with wider affordability., CorningIt supplies specialty pharmaceutical glass for vials and cartridges, and that business grows with total dose volume in the market.25%
- Distributors and sellers move drugs to patients, so cheaper prices and more users mean more business flowing through their networks. · Hims & Hers HealthIt sells weight-loss treatment directly to consumers at prices below branded shots, making it a pure bet on the cheap, high-volume future this take predicts., McKessonIt moves drugs from factories to pharmacies and gets paid on each dose shipped, so falling prices and more prescriptions multiply the volume it handles., CencoraIt is a major drug distributor that has called out weight-loss drug shipments as a growth driver, clipping a fee on every dose distributed., Cardinal HealthIt is one of three companies shipping nearly all US drugs, so owning all three captures weight-loss volume growth across the entire distribution system.20%
- Giant drugmakers pushing their own weight-loss shots and pills toward approval are the competition that could break the current duopoly's pricing power. · AmgenIts shot might only need dosing once a month, which undercuts weekly injections on convenience and could undercut them on price., AstraZenecaIt licensed an oral GLP-1 pill it plans to make cheap enough for mass markets, which is exactly the price pressure this take is betting on., PfizerPfizer has substantial capital and has publicly committed to building a GLP-1 obesity franchise through acquisition or licensing, making its deal-making capabilities central to whether it gains a foothold in this market., MerckIt licensed an oral GLP-1 candidate from China, a cheaper path into the market that fits the expectation that pills undercut shots on price.20%
- Smaller biotechs whose whole company is a rival weight-loss drug offer the biggest payoff if one reaches market and wins share from current leaders. · Viking TherapeuticsIts shot posted weight-loss results in trials that rival the best from current leaders, and it is also working on a pill version., Structure TherapeuticsIt is building small-molecule GLP-1 pills, which are cheaper to make and easier to scale than injections, the exact mechanism that could crack current pricing., SPDR S&P Biotech ETFIt holds a broad slice of biotech companies to catch winners beyond individual picks, capturing sector-wide development if money keeps flowing into obesity drugs., AltimmuneIts shot aims to beat current drugs on preserving muscle while losing fat, a differentiated angle if its trial data stays competitive.18%
- More competitors means more clinical trials needed, and contract research firms get paid to run those trials whether the drugs succeed or fail. · IQVIA HoldingsIt is the biggest firm running clinical trials, and every challenger racing a rival drug through development has to pay it to conduct those studies., Medpace HoldingsIt runs trials specifically for small biotechs and gets paid whether those drugs succeed or fail, as long as companies keep funding obesity trials.8%
- Cash10%